NCT05266131

Brief Summary

Obstructive sleep apnea (OSA) and hypertension are closely associated diseases. Here we characterized the differences in the gut microbiome which is affected by the two diseases, when the two diseases coexist or are present alone. Fifty-two consecutive patients who underwent polysomnography (PSG) were enrolled and divided into four groups: without OSA or hypertension (OSA0HT0), OSA without hypertension (OSA1HT0), hypertension without OSA (OSA0HT1), and with OSA and hypertension (OSA1HT1). Fecal specimens were collected for 16S rRNA sequencing and the characteristics of community richness, diversity, and composition of the gut microbiome and their relationship with disease were analyzed using bioinformatics methods.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
52

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jul 2017

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2017

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2017

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 28, 2018

Completed
3.7 years until next milestone

First Submitted

Initial submission to the registry

February 1, 2022

Completed
1 month until next milestone

First Posted

Study publicly available on registry

March 4, 2022

Completed
Last Updated

October 22, 2024

Status Verified

October 1, 2024

Enrollment Period

5 months

First QC Date

February 1, 2022

Last Update Submit

October 21, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • 1. Comparisons of the relative community richness of Clostridia of the gut microbiota in OSA0HT0,OSA0HT1,OSA1HT0 and OSA1HT1 group.

    from July 2017 to November 2017

Secondary Outcomes (3)

  • 2. Comparison of the overall community diversity of the gut microbiome in OSA0HT0,OSA0HT1,OSA1HT0 and OSA1H1 group.

    from July 2017 to November 2017

  • 3. Comparison of the overall community richness of the gut microbiome in OSA0HT0,OSA0HT1,OSA1HT0 and OSA1H1 group.

    from July 2017 to November 2017

  • 4. Relationship between alpha diversity of the gut microbiome and hypoxia burden of PSG study.

    from July 2017 to November 2017

Study Arms (4)

OSA0HT0

without OSA or hypertension (OSA0HT0)

OSA1HT0

OSA without hypertension (OSA1HT0)

OSA0HT1

hypertension without OSA (OSA0HT1)

OSA1HT1

with OSA and hypertension (OSA1HT1)

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Participants were divided into four groups according to whether they had a confirmed diagnosis of essential HT and OSA (AHI ≥15 beats/h (International Classification of Sleep Disorders (3rd edition) ), as follows. Individuals without OSA and HT belonged to group OSA0HT0; individuals with both OSA and HT were in group OSA1HT1; individuals without OSA but with HT were in group OSA0HT1; and individuals with OSA but without HT were in the group OSA1HT0.

You may qualify if:

  • age 18 years or older
  • outpatients and inpatients who underwent a PSG study for snoring
  • those who volunteered for this study and signed an informed consent form

You may not qualify if:

  • patients who were treated for OSA (regular CPAP therapy, oral appliances, maxillofacial surgery, etc.) prior to enrolment
  • patients with secondary HT with a clear primary cause
  • those with a history of dyspeptic disease (history of gastrointestinal surgery, peptic ulcer, inflammatory bowel disease, chronic pancreatitis, etc.)
  • those who had organ insufficiency, were receiving immune agents or glucose
  • those who had received antibiotic treatment in the last 2 months or had taken probiotic products (yogurt, milk, cheese, etc.) continuously (daily) for the last 2 months
  • Alcohol or drug dependency

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Peking University First Hospital

Beijing, Beijing Municipality, 100034, China

Location

MeSH Terms

Conditions

Sleep Apnea, ObstructiveHypertension

Condition Hierarchy (Ancestors)

Sleep Apnea SyndromesApneaRespiration DisordersRespiratory Tract DiseasesSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System DiseasesVascular DiseasesCardiovascular Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

February 1, 2022

First Posted

March 4, 2022

Study Start

July 1, 2017

Primary Completion

November 30, 2017

Study Completion

May 28, 2018

Last Updated

October 22, 2024

Record last verified: 2024-10

Locations